The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
Open accessAbstract
Purpose: Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent activity in these patients and has demonstrated synergy with capecitabine in this setting. This study was designed to compare ixabepilone plus capecitabine versus capecitabine alone in anthracycline-pretreated or -resistant and taxane-resistant locally advanced or metastatic breast cancer. Patients and Methods: Seven hundred fifty-two patients were randomly assigned to ixabepilone 40 mg/m 2 intravenously on day 1 of a 21-day cycle plus capecitabine 2,000 mg/m 2 orally on days 1 through 14 of a 21-day cycle, or capecitabine alone 2,500 mg/m 2 on the same schedule, in this international phase III study. The primary end point was progression-free survival evaluated by blinded independent review. Results: Ixabepilone plus capecitabine prolonged progression-free survival relative to capecitabine (median, 5.8 v 4.2 months), with a 25% reduction in the estimated risk of disease progression (hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P = .0003). Objective response rate was also increased (35% v 14%; P < .0001). Grade 3/4 treatment-related sensory neuropathy (21% v 0%), fatigue (9% v 3%), and neutropenia (68% v 11%) were more frequent with combination therapy, as was the rate of death as a result of toxicity (3% v 1%, with patients with liver dysfunction [≥ grade 2 liver function tests] at greater risk). Capecitabine-related toxicities were similar for both treatment groups. Conclusion: Ixabepilone plus capecitabine demonstrates superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Self-citationMolecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Haffty, B. G., Yang, Q., Reiss, M., Kearney, T., Higgins, S. A., Weidhaas, J., Harris, L., Hait, W., & Toppmeyer, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5664 · Cited by 1,084
O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W.-Y., Mauriac, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.002 · Cited by 1,081
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.-U., Brown, C. S., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 783
Hortobagyi, G. N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391407 · Cited by 781
Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472
Perez, E. A., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman, L., Viens, P., Cai, C., Mullaney, B., Peck, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3849 · Cited by 393
Self-citationFumoleau, P., Largillier, R., Clippe, C., Dièras, V., Orfeuvre, H., Lesimple, T., Culine, S., Audhuy, B., Serin, D., Curé, H., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.007 · Cited by 305
Thomas, E., Tabernero, J., Fornier, M., Conté, P., Fumoleau, P., Lluch, A., Vahdat, L. T., Bunnell, C. A., Burris, H. A., Viens, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9102 · Cited by 290
Self-citationLow, J. A., Wedam, S. B., Lee, J. J., Berman, A. W., Brufsky, A., Yang, S. X., Poruchynsky, M. S., Steinberg, S. M., Mannan, N., Fojo, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.024 · Cited by 215
The Biology and Medicinal Chemistry of Epothilones
Wartmann, M., & Altmann, K. (2012) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011023354489 · Cited by 182
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Bernard-Marty, C., Cardoso, F., & Piccart, M. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-617 · Cited by 177
Pignata, S., Placido, S. D., Biamonte, R., Scambia, G., Vagno, G. D., Colucci, G., Febbraro, A., Marinaccio, M., Lombardi, A. V., Manzione, L., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-5 · Cited by 126
Valero, V., & Hortobágyi, G. N. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.071 · Cited by 64
Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)
Yost, K. J., Yount, S., Eton, D. T., Silberman, C., Heyes, A., & Cella, D. F. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-5024-3 · Cited by 28
Cited by
Microtubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2803 · Cited by 1,120
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationChemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Drugs that target dynamic microtubules: A new molecular perspective
Stanton, R. A., Gernert, K. M., Nettles, J. H., & Aneja, R. (2011) · Medicinal Research Reviews · doi:10.1002/med.20242 · Cited by 526
Metadata
- Authors
- Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., Xu, B., Campone, M., Lerzo, G. L., Peck, R. A., Mukhopadhyay, P., Vahdat, L. T., & Roché, H. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-11-20
- Volume
- 25
- Issue
- 33
- Pages
- 5210-5217
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2127340468
- Cited by
- 481
- References
- 18
- FWCI
- 29.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.